Is dienogest a convenient treatment option for cesarean scar endometriosis or should it be treated surgically?
Autor: | Seckin KD; Istinye University, Department of Obstetrics and Gynecology, Istanbul, Turkey. Electronic address: doga_seckin@hotmail.com., Kadirogullari P; Acıbadem University Atakent Hospital, Department of Obstetrics and Gynecology, Istanbul, Turkey. |
---|---|
Jazyk: | angličtina |
Zdroj: | European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2023 Mar; Vol. 282, pp. 110-115. Date of Electronic Publication: 2023 Jan 23. |
DOI: | 10.1016/j.ejogrb.2023.01.025 |
Abstrakt: | Objectives: Endometriosis-related conditions such as subcutaneous endometriosis have been frequently seen in recent years, and dienogest or surgical excision is generally preferred as a treatment option. Our aim in this study is to determine which treatment option will be more effective in reducing the symptoms of patients with cesarean scar endometriosis. Study design This prospective study was performed with 21 patients diagnosed with cesarean scar endometriosis. The demographic features of the patients, lesion sizes before and after medical and surgical treatment, VAS scores and Ca-125 levels were recorded. VAS scores and lesion sizes were compared before-after medical treatment and before-after surgery in same group. Results: A total of 18 women were identified, with a mean age of 32.3 ± 5.7 years. No significant decrease in lesion size was observed in the 1st and 6th-month controls after the use of dienogest (p > 0,05), while a significant decrease in VAS scores was detected (p < 0,05). After surgery, the decrease in both lesion size and VAS scores was found statistically significant (p < 0,05). Conclusion: Dienogest, which is frequently used in the medical treatment of pelvic and ovarian endometriosis, reduces pain minimally in cesarean scar endometriosis but does not provide a change in lesion size. Therefore, surgical treatment of cesarean scar endometriosis seems to be more effective in reducing pain and decreasing the size of the lesions. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2023. Published by Elsevier B.V.) |
Databáze: | MEDLINE |
Externí odkaz: |